How effective is Vandetanib in treating thyroid cancer?

Vandetanib is considered one of the landmark targeted drugs in the treatment of medullary thyroid cancer (thyroid cancer). It significantly extends the progression-free survival of patients by inhibiting tumor cell growth signals and angiogenesis. Main clinical research results show that vandetanib can effectively slow down the progression of the disease and prolong the disease control time of patients. Compared with the control group, patients who took vandetanib could survive for about 30 more months without disease progression. This result shows that it can significantly inhibit the spread of tumors and improve their quality of life.

In adolescent patients, vandetanib also showed good efficacy. Studies have shown that after treatment, the tumor volume of some pediatric patients was significantly reduced, the stable period of the disease was prolonged, and the tolerance was generally controllable. This shows that vandetanib is not only effective in adult medullary thyroid cancer, but also brings new treatment hope for hereditary MTC in children.

However, vandetanib is not suitable for all types of thyroid cancer, especially cases with differentiated thyroid cancer or withoutRET mutations, and its efficacy is limited. In addition, drugs may cause side effects such as QT interval prolongation, skin photosensitivity, diarrhea, and fatigue. Therefore, patients need to undergo regular ECG monitoring and liver and kidney function evaluation during treatment. Doctors usually adjust the dosage according to individual conditions to ensure efficacy while reducing the risk of adverse reactions.

Overall, vandetanib is regarded as one of the important targeted drugs for the treatment of advanced or metastatic medullary thyroid cancer. It provides a new treatment approach for patients whose disease cannot be controlled through surgery, and also promotes the era of precision treatment of thyroid cancer. With in-depth research on RET pathway inhibitors, it is expected to develop a new generation of drugs that are more selective and less toxic in the future, bringing longer-term survival benefits to patients.

Reference materials:https://www.drugs.com/caprelsa.html